Owkin Expands Oncology Pipeline with AI and EP2/EP4 Dual Inhibitor from Idorsia
Owkin, a pioneering TechBio company leveraging advanced causal* AI for precision drug discovery, has announced a significant expansion of its …
#Oncology
Tempus AI Files S-1 Registration to Go Public
Tempus AI has officially filed its S-1 registration statement with the Securities and Exchange Commission (SEC), marking a significant step …
AstraZeneca to Establish $1.5 Billion ADC Manufacturing Facility in Singapore
AstraZeneca has announced plans to construct a $1.5 billion manufacturing facility in Singapore dedicated to producing antibody-drug conjugates (ADCs), a …
Insilico Medicine Initiates Phase I Clinical Trial for Novel QPCTL Inhibitor
Insilico Medicine, a biotechnology company specializing in generative artificial intelligence, has begun dosing patients in the first clinical trial for …
Troubling Safety Data Overshadows Efficacy in MacroGenics' Phase 2 Study
MacroGenics, a biotechnology company, has reported concerning safety outcomes in its phase 2 trial of vobramitamab duocarmazine, a B7-H3-directed antibody-drug …
Conducting a Cellular Symphony With Life Saving Combination Therapies
I always think of the Jeff Goldblum quote in Jurassic Park where he says "life finds a way" when I …
Playing Chess Against Cancer: A Pharmaceutical, Biotechnological, and Clinical Guide to Modern Day Oncologic Treatment Cartography
We are witnessing a revolution in cancer therapeutics that is truly bewildering. The number of novel drugs with unique mechanisms …
Drowning in Data: A Data Science Primer for a Translational Scientist
In 1945 the volume of human knowledge doubled every 25 years. Now, that number is 12 hours [1]. With our …
Predicting a Patient’s Future with a Crystal Ball Comprised of Cell-free DNA
Chapter 1 of a 3-chapter Hitchhiker’s guide to cell-free DNA for travelers of all backgrounds and expertise. Even though I’ve …
Wielding New Cancer Weapons Forged in Cell-Free DNA: A Wake Up Call For The Entire Biotech Industry
Advances in computational biology, precision medicine, artificial intelligence/machine learning, etc., are launching us into a world where strategic control points …
Choosing Cancer Weapons With the Best Aim
In oncology, we do the best we can. We give drugs with 10-20% chances of working because we have nothing …
Auron Therapeutics Raises $48M to Advance AI-platform and Differentiation Therapy for Cancer
Auron Therapeutics, a biopharmaceutical company focused on developing therapies that target dysregulated differentiation and cellular plasticity for treating cancer, just …